SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming 62(nd) Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 28 - October 2, 2026 in Milan, Italy. Presented data will highlight SAB BIO’s lead program, SAB-142, a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of Stage 3 T1D.

“We are honored to present and participate at the EASD Annual Meeting, which provides an important opportunity to engage with the global diabetes community as type 1 diabetes research increasingly focuses on preserving endogenous insulin production and modifying the course of disease,” said Alexandra Kropotova, M.D., MBA, Chief Medical Officer, SAB BIO. “Our presentations highlight SAB-142 Phase 1 data, including its mechanism of action, potential for safe redosing, and early evidence of C-peptide preservation. We look forward to engaging with the scientific community as SAB-142 continues to advance through the registrational SAFEGUARD study.”